A Phase I Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (MAB) in B-Cell Lymphoma Patients with Prior Exposure to Rituximab.

Drug Category : Array
Conference Category : Array
Lead Author : Changchun D, O'Connor O, et al.
Published Date : 30/05/2014
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/ASCO2014-Poster-8524.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top